Drug Abuse Liability Services
PsychoGenics has been a leader in the field of drug abuse liability for over a decade, specializing in the validation...
PsychoGenics Drug Discovery Featured in Nature Biopharma Dealmakers
A phenotypic high-throughput approach to neuropsychiatric drug discovery Using its SmartCube platform along with machine learning algorithms, PsychoGenics has a...
Preclinical Electrophysiology Services
Explore our two broad categories of electrophysiology services: Add our e-phys expertise to your program and propel your next breakthrough....
Characterization of a Rat Model of CMT2A
The below data was made possible by CMTA, the Charcot-Marie-Tooth Association. Charcot-Marie-Tooth (CMT) disorders are a family of related disorders that...
Clinical Catch-Up: Updates in Solid Tumors, ALS, Migraine and More
By Vanessa Doctor, RN · Sep 22, 2022 · BioSpace It’s been a busy week across the clinical development space, with...
Terms of Use
Terms PsychoGenics, Inc. (also referred to as “PGI”, “we” or “our”) operates www.psychogenics.com (“Website”) to provide online access to information about PGI...
Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration
Multi-year drug discovery collaboration leveraging behavioral and physiological phenotypic screening and machine learning to identify novel neuropsychiatric drug candidates Karuna...
Characterization of a Mouse Model of CMT2E
The below data was made possible by CMTA, the Charcot-Marie-Tooth Association. Charcot-Marie-Tooth (CMT) disorders are a family of related disorders that...
GBR Connect Series – Interview with Emer Leahy, PsychoGenics
Can you give an overview of how business has evolved for PsychoGenics over the past year? There are two sides...
SmartCube® In Vivo AI Platform for Compound Screening
High-Throughput Phenotypic Drug Discovery SmartCube® is a cutting-edge automated testing platform that guides mice through a series of challenges using...